Aimmune Therapeutics, Inc. AIMT was a big mover last session, as its shares rose roughly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday’s rally reverses the recent downtrend for the company, as the stock is now down almost 20% in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Aimmune currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment